Market Overview

UPDATE: Morgan Stanley Downgrades Mylan to Equal-Weight Following Outperformance

Share:
Related MYL
Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent
Cramer Weighs In On Transocean LTD, Mylan Inc And Honda Motor Co Ltd
Mylan Faces Short-Term News Flow And Reputational Risk (Seeking Alpha)

Morgan Stanley downgraded Mylan Inc. (NASDAQ: MYL) from Overweight to Equal-weight and removed the price target of $27.00.

Morgan Stanley commented, "Mylan is above our previous $27 price target, and we are downgrading from OW to EW on a more balanced risk-reward. The market now appears to be pricing in better growth prospects in EMEA and the potential for accretive M&A."

Mylan closed at $27.91 on Monday.

Latest Ratings for MYL

DateFirmActionFromTo
Jan 2015Deutsche BankMaintainsBuy
Sep 2014ISI GroupInitiates Coverage on
Aug 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (MYL)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional